Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions.

ABSTRACT: Background:To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods:PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary:Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Fut

SUBMITTER: Bender U 

PROVIDER: S-EPMC6878933 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature